Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Jan 7;13(1):68.
doi: 10.3390/pharmaceutics13010068.

Promising Adjuvants and Platforms for Influenza Vaccine Development

Wandi Zhu  1 , Chunhong Dong  1 , Lai Wei  1 , Bao-Zhong Wang  1
Affiliations
Review

Promising Adjuvants and Platforms for Influenza Vaccine Development

Wandi Zhu et al. Pharmaceutics. .

Abstract

Influenza is one of the major threats to public health. Current influenza vaccines cannot provide effective protection against drifted or shifted influenza strains. Researchers have considered two important strategies to develop novel influenza vaccines with improved immunogenicity and broader protective efficacy. One is applying fewer variable viral antigens, such as the haemagglutinin stalk domain. The other is including adjuvants in vaccine formulations. Adjuvants are promising and helpful boosters to promote more rapid and stronger immune responses with a dose-sparing effect. However, few adjuvants are currently licensed for human influenza vaccines, although many potential candidates are in different trials. While many advantages have been observed using adjuvants in influenza vaccine formulations, an improved understanding of the mechanisms underlying viral infection and vaccination-induced immune responses will help to develop new adjuvant candidates. In this review, we summarize the works related to adjuvants in influenza vaccine research that have been used in our studies and other laboratories. The review will provide perspectives for the utilization of adjuvants in developing next-generation and universal influenza vaccines.

Keywords: adjuvants; influenza vaccine; nanoparticles.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
A diagram of different self-adjuvanted nanoparticle (NP) platforms. (A) Au NPs. (B) virus-like particles (VLP)s. (C) Protein NPs. (D) biodegradable synthetic polymeric (PLGA) NPs. (E) Lipid NPs.
See this image and copyright information in PMC

References

    1. Centers for Disease Control and Prevention Estimated Influenza Illnesses, Medical visits, Hospitalizations, and Deaths in the United States—2019–2020 Influenza Season. [(accessed on 6 October 2020)]; Available online: https://www.cdc.gov/flu/about/burden/2019-2020.html#anchor_1601407136591.
    1. Valkenburg S.A., Rutigliano J.A., Ellebedy A.H., Doherty P.C., Thomas P.G., Kedzierska K. Immunity to seasonal and pandemic influenza A viruses. Microbes Infect. 2011;13:489–501. doi: 10.1016/j.micinf.2011.01.007. - DOI - PMC - PubMed
    1. Koutsakos M., Kedzierska K., Subbarao K. Immune Responses to Avian Influenza Viruses. J. Immunol. 2019;202:382–391. doi: 10.4049/jimmunol.1801070. - DOI - PubMed
    1. Centers for Disease Control and Prevention Seasonal Influenza Vaccine Safety: A Summary for Clinicians. [(accessed on 4 September 2020)]; Available online: https://www.cdc.gov/flu/professionals/vaccination/vaccine_safety.htm.
    1. Centers for Disease Control and Prevention U.S. Influenza Surveillance System: Purpose and Methods. [(accessed on 6 October 2020)]; Available online: https://www.cdc.gov/flu/weekly/overview.htm.

LinkOut - more resources